Skip to content

Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder

Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04432493
Enrollment
81
Registered
2020-06-16
Start date
2020-02-20
Completion date
2022-08-31
Last updated
2024-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-use Disorder

Keywords

Transcranial magnetic stimulation, Reward processing, Cognitive control

Brief summary

The primary aims of this study are to identify impaired cognitive control in opioid use disorder (OUD) and subsequently to examine the effects of transcranial magnetic stimulation (TMS) on reward processing, as measured by the reward positivity (an electrophysiological signal) in people with OUD. To this end, the investigators will adopt a randomized sham-controlled trial to evaluate the efficacy of Ri-TMS on cognitive control in OUD. The investigators hypothesize that Ri-TMS will be successful in modulating the reward positivity in opioid users in the active TMS condition.

Detailed description

The design is primarily a randomized control-trial design, comparing the effects of placebo (sham) and active TMS stimulation on reward processing across two groups of participants - healthy controls and opioid users. Participants will be asked to engage in a virtual T-maze task, a reward-based choice task that elicits robust reward positivities. During this task participants will receive simultaneous EEG/TMS, while they engage in the virtual T-maze decision making task, used in our previous reward positivity studies on SUDs. ERPs will be recorded throughout the T-Maze task, and the reward positivity will be measured as the difference in maximum amplitude between reward and no-reward feedback conditions. The TMS coil will be positioned using a an Adept Viper s850 robotic arm (SmartMove, ANT Neuro, Enschede, The Netherlands), providing precise targeting of the predetermined left dorsolateral prefrontal (DLPFC) coordinate (\< 10 mm from the scalp, orientated at a 45º angle). Participants in the active TMS condition will receive rTMS pulses throughout the duration of the T-Maze task, with a maximum of 2000 pulses delivered to each participant. Identical parameters will be applied to the SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation.

Interventions

rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.

Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.

Sponsors

Rutgers University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants will be blinded as to TMS condition (active or sham)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Native English speakers * Males and Females aged 18-55 years old * Ability to provide informed written or verbal consent * Opioid dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test opioid dependence score), or * Healthy controls with no history of significant substance use

Exclusion criteria

* Un-correctable visual impairment * Uninterruptable central nervous system medication * TMS contraindications (e.g., pregnancy, braces, history of seizures, metal implants). * History of neurological or psychiatric illness * Diagnosed learning disability * History of significant head injury (loss of consciousness for more than five minutes) * Substance abuse (Participants who score above 39.5 on the Global Continuum of Substance Risk scale of the Alcohol, Smoking and Substance Involvement Screening Test - controls only) * Use of psychoactive or vasoactive medications

Design outcomes

Primary

MeasureTime frameDescription
Reward PositivityDay 0 (day of testing)The reward positivity is an event-related brain potential, sensitive to reward feedback. The reward positivity will be measured during the t-maze task, where participants will receive feedback on choices (Reward, No-reward). Reward positivity amplitude will be determined by identifying the maximum absolute amplitude of the difference wave within a 200- to 400-ms window following feedback onset. The reward positivity will be evaluated along front-central electrodes (Fz, FCz, Cz).

Countries

United States

Participant flow

Participants by arm

ArmCount
Active TMS - OUD
Opioid Use Disorder (OUD) Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses Active repetitive transcranial magnetic stimulation (rTMS): rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
16
Sham TMS - OUD
Identical parameters will be applied to the Opioid Use Disorder (OUD) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation Sham repetitive transcranial magnetic stimulation (rTMS): Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
18
Active TMS - HC
Healthy Control (HC) Participants in the active condition will receive repetitive TMS (rTMS), delivered at 110% of participants' resting motor threshold at 10 Hz continuously over the predefined DLFPC target for a total of 2000 pulses Active repetitive transcranial magnetic stimulation (rTMS): rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
22
Sham TMS - HC
Identical parameters will be applied to the Healthy Control (HC) SHAM group with the exception that the TMS coil will be flipped 180º to mimic auditory stimulation Sham repetitive transcranial magnetic stimulation (rTMS): Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
25
Total81

Baseline characteristics

CharacteristicSham TMS - OUDActive TMS - HCSham TMS - HCActive TMS - OUDTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
18 Participants22 Participants25 Participants16 Participants81 Participants
Age, Continuous46 years
STANDARD_DEVIATION 19
36 years
STANDARD_DEVIATION 12
34 years
STANDARD_DEVIATION 11
42 years
STANDARD_DEVIATION 9
39 years
STANDARD_DEVIATION 11
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants2 Participants2 Participants1 Participants5 Participants
Race (NIH/OMB)
Black or African American
12 Participants10 Participants8 Participants10 Participants40 Participants
Race (NIH/OMB)
More than one race
0 Participants3 Participants4 Participants1 Participants8 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
6 Participants7 Participants11 Participants4 Participants28 Participants
Region of Enrollment
United States
18 μV (Microvolts22 μV (Microvolts25 μV (Microvolts16 μV (Microvolts81 μV (Microvolts
Sex: Female, Male
Female
6 Participants10 Participants12 Participants5 Participants33 Participants
Sex: Female, Male
Male
12 Participants12 Participants13 Participants11 Participants48 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 180 / 220 / 25
other
Total, other adverse events
0 / 160 / 180 / 220 / 25
serious
Total, serious adverse events
0 / 160 / 180 / 220 / 25

Outcome results

Primary

Reward Positivity

The reward positivity is an event-related brain potential, sensitive to reward feedback. The reward positivity will be measured during the t-maze task, where participants will receive feedback on choices (Reward, No-reward). Reward positivity amplitude will be determined by identifying the maximum absolute amplitude of the difference wave within a 200- to 400-ms window following feedback onset. The reward positivity will be evaluated along front-central electrodes (Fz, FCz, Cz).

Time frame: Day 0 (day of testing)

ArmMeasureValue (MEAN)Dispersion
Active TMS - OUDReward Positivity-5.2 μV (microvolts)Standard Deviation 2
Sham TMS - OUDReward Positivity-2.3 μV (microvolts)Standard Deviation 3
Active TMS - ControlsReward Positivity-4.4 μV (microvolts)Standard Deviation 3
Sham TMS - ControlsReward Positivity-4.6 μV (microvolts)Standard Deviation 3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026